ArticleNeurology(R) neuroimmunology & neuroinflammation2019
Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
Article in Neurology(R) neuroimmunology & neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed.
- Prognostic Modeling for the Failure of Intravenous Methylprednisolone and the Risk of Visual Disability in AQP4-IgG Positive NMOSD-ON.Translational vision science & technology · 2026Trial
- Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial.BMC neurology · 2020Trial
- Optimal strategies for treatment discontinuation in MOG antibody-associated disease.Brain : a journal of neurology · 2026Article
- Article
- Changepoint analysis of longitudinal OCT in optic neuritis: Structural stabilization dynamics and clinical correlates.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Myelin oligodendrocyte glycoprotein antibody-associated disease after transforaminal lumbar interbody fusion surgery: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.Brain : a journal of neurology · 2026Observational
- OCT-Based Differentiation of First Acute Optic Neuritis: An International Study of 111 Patients With NMOSD and MOGAD.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Significant Visual Field Defects Persist Despite Excellent Visual Acuity Following Optic Neuritis in Myelin-Oligodendrocyte Glycoprotein Associated Disease.Neuro-ophthalmology (Aeolus Press) · 2026Article
- Rethinking routine lumbar puncture in isolated optic neuritis: results from a large cohort study.Journal of neurology · 2025Article
- The clinical profile and therapeutic outcome of patients diagnosed with "atypical" optic neuritis.International ophthalmology · 2025Article
- Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onset.Multiple sclerosis and related disorders · 2025Article
- The Kappa Free Light Chains Index and Central Vein Sign: Two New Biomarkers for Multiple Sclerosis Diagnosis.Neurology and therapy · 2025Review
- Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic Neuritis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Article
- Is a Benign Disease Course Possible in Untreated AQP4-IgG NMOSD?European journal of neurology · 2025Article
- A roadmap to increasing access to AQP4-Ig testing for NMOSD: expert recommendations.Arquivos de neuro-psiquiatria · 2025Article
- Determinants of long-term disability in chronic inflammatory demyelinating polyradiculoneuropathy: A multicenter Korea/UK study of 144 patients.European journal of neurology · 2025Article
- Challenges in the Diagnosis and Management of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).Annals of Indian Academy of Neurology · 2025Article
- Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate whether visual disability which is known to accumulate by poor recovery from optic neuritis (ON) attacks can be lessened by early treatment, we investigated whether the time from symptom onset to high-dose IV methylprednisolone (IVMP) affected visual recovery. Methods: A retrospective study was performed in a consecutive cohort of patients following their first aquaporin-4 (AQP4)-IgG or myelin oligodendrocyte glycoprotein (MOG)-IgG-ON. Best-corrected visual acuity (BCVA) in ON eyes at 3 months (BCVA3mo) was correlated with time to IVMP (days). In cases of bilateral ON, 1 eye was randomly selected. Results: A total of 29 of 37 patients had ON (27 AQP4-seropositive neuromyelitis optica spectrum disorder [NMOSD] and 9 MOG-IgG-ON), 2 of whom refused treatment. Of the 27 patients included, 10 presented later than 7 days from onset. The median BCVA3mo of patients treated >7 days was 20/100 (interquartile range 20/100-20/200). Patients treated >7 days had an OR of 5.50 (95% CI 0.88-34.46, Conclusions: In this retrospective study of ON with AQP4 and MOG-IgG, even a 7-day delay in IVMP initiation was detrimental to vision. These results highlight the importance of early treatment for the long-term visual recovery in this group of patients. A prospective, multicenter study of the effects of timing of IVMP is currently underway. Classification of evidence: This study provides Class IV evidence that hyperacute treatment of AQP4 and MOG-ON with IVMP increases the chance for good visual recovery (20/20 vision) and that even a greater than 7-day delay in treatment is associated with a higher risk for poor visual recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.